Intas Pharmaceuticals Limited — Escitalopram Exporter Profile
Indian Pharmaceutical Exporter · #11 for Escitalopram · $4.1M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #11 Indian exporter of Escitalopram with $4.1M in export value and 391 verified shipments. Intas Pharmaceuticals Limited holds a 2.1% market share in Escitalopram exports across 10 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Escitalopram Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Escitalopram?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $823.6K | 136 | 47.0% |
| SOUTH AFRICA | $302.2K | 23 | 17.2% |
| HONG KONG | $266.1K | 25 | 15.2% |
| UNITED KINGDOM | $166.6K | 31 | 9.5% |
| POLAND | $90.8K | 32 | 5.2% |
| LATVIA | $78.5K | 3 | 4.5% |
| ITALY | $13.5K | 12 | 0.8% |
| MAURITIUS | $9.6K | 5 | 0.5% |
| GREECE | $2.1K | 4 | 0.1% |
| MALTA | $828 | 125 | 0.0% |
Intas Pharmaceuticals Limited exports Escitalopram to 10 countries. The largest destination is NETHERLANDS accounting for 47.0% of Intas Pharmaceuticals Limited's Escitalopram shipments, followed by SOUTH AFRICA (17.2%) and HONG KONG (15.2%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Escitalopram from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | MALTA | $492.0K | 110 |
| ACCORD HEALTHCARE C/O UPD LEA GLEN | SOUTH AFRICA | $296.1K | 22 |
| BROCACEF NL : HUB | NETHERLANDS | $224.1K | 51 |
| BROCACEF NL : DUTCH | NETHERLANDS | $129.1K | 21 |
| ACCORD UK | UNITED KINGDOM | $100.1K | 12 |
| TO BANK | HONG KONG | $65.5K | 5 |
| BROCACEF NL:EU HUB | NETHERLANDS | $60.1K | 6 |
| TO THE ORDER., | HONG KONG | $58.3K | 6 |
| I & C (HONGKONG) LIMITED | HONG KONG | $57.8K | 5 |
| BROCACEF NL DUTCH | NETHERLANDS | $50.0K | 1 |
Intas Pharmaceuticals Limited supplies Escitalopram to 29 buyers globally. The largest buyer is TO THE ORDER (MALTA), followed by ACCORD HEALTHCARE C/O UPD LEA GLEN (SOUTH AFRICA) and BROCACEF NL : HUB (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Escitalopram Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $109.7M worth of Escitalopram through 5,457 shipments from 231 suppliers to 95 countries, serving 628 buyers globally. Intas Pharmaceuticals Limited contributes $4.1M to this total, accounting for 2.1% of India's Escitalopram exports. Intas Pharmaceuticals Limited ships Escitalopram to 10 countries through 29 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Escitalopram Exports?
Intas Pharmaceuticals Limited's average Escitalopram shipment value is $10.4K per consignment, based on 391 shipments totaling $4.1M. The largest destination is NETHERLANDS (47.0% of Intas Pharmaceuticals Limited's Escitalopram exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Escitalopram Exporters?
Intas Pharmaceuticals Limited ranks #11 among 231 Indian Escitalopram exporters with a 2.1% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($22.5M), SANDOZ PRIVATE LIMITED ($12.9M), TORRENT PHARMACEUTICALS LTD ($12.1M). Intas Pharmaceuticals Limited processed 391 shipments to 10 destination countries.
What Escitalopram Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI ESCITALOPRAM 20MG 7X14T(ACCORD-SWEDEN AS PER INVOICE | $111.3K | 12 |
| PHARM DRUG&MED:ESCITALOPRAM 10MG 7X14T(ACCORD-SWEDEN)ESCITALOPRAM ACCORD 10MG EACH FILM COATED TABLET CONTAIN (ASPERINV) | $110.4K | 6 |
| PH.DRU.& MED.: ACCORD ESCITALOPRAM TABLETS 20MG (EACH TABLET CONTAINS: ESCITALOPRAM 20MG) [2X14T PER PACK] | $100.0K | 2 |
| PH.DRU.& MED.: ACCORD ESCITALOPRAM TABLETS 10MG (EACH TABLET CONTAINS: ESCITALOPRAM 10MG) [2X14T PER PACK] | $100.0K | 2 |
| PHARMA DRUGS & MEDI ESCITALOPRAM 10MG 2X | $57.8K | 12 |
| PHARMA DRUGS & MEDI ESCITALOPRAM 10MG 7X | $52.4K | 9 |
| PHARMACEUTICAL DRUGS AND MEDICINE ESCITALOPRAM 10MG 2X14T(ACCORD-NETHERLAND EACHFILM COATED TABLET CONTAINS ESCITALOPR | $50.0K | 1 |
| PHARMA DRUGS & MEDI ESCITALOPRAM 10MG 2X14T(ACCORD-NETHERLA AS PER INVOICETBS | $45.4K | 9 |
| PHARM DRUG MED ESCITALOPRAM IQB 10MG 2X14T ACO IQ EACH TABLET CONTAINS 10 MG ESCITALOPRAM AS OXALATE ASPERINV | $39.6K | 3 |
| PHARMA DRUGS & MEDI ESCITALOPRAM 20MG 7X | $38.2K | 2 |
Intas Pharmaceuticals Limited exports 186 distinct Escitalopram formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI ESCITALOPRAM 20MG 7X14T(ACCORD-SWEDEN AS with 12 shipments worth $111.3K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Escitalopram to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Escitalopram to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Escitalopram Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | TORRENT PHARMACEUTICALS LIMITED | $5.4M | 121 | 11 | $44.6K |
| 10 | IPCA LABORATORIES LIMITED | $4.1M | 108 | 7 | $38.3K |
| 11 | INTAS PHARMACEUTICALS LIMITED ★ | $4.1M | 391 | 10 | $10.4K |
| 1 | MEDISPRAY LABORATORIES PRIVATE LIMITED | $3.9M | 77 | 1 | $50.0K |
| 12 | MICRO LABS LIMITED | $3.0M | 130 | 10 | $23.2K |
Intas Pharmaceuticals Limited ranks #11 among 231 Indian Escitalopram exporters. Average shipment value of $10.4K compared to the market average of $474.7K. The closest competitors by value are TORRENT PHARMACEUTICALS LIMITED and IPCA LABORATORIES LIMITED.
Which Indian Ports Ship Escitalopram Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 652 | 11.9% |
| SAHAR AIR | 555 | 10.2% |
| NHAVA SHEVA SEA (INNSA1) | 471 | 8.6% |
| HYDERABAD ICD | 369 | 6.8% |
| DELHI AIR CARGO ACC (INDEL4) | 303 | 5.6% |
| DELHI AIR | 287 | 5.3% |
| HYDERABAD ICD (INSNF6) | 243 | 4.5% |
| HYDERABAD AIR | 217 | 4.0% |
What Other CNS & Psychiatric Products Does Intas Pharmaceuticals Limited Export?
Intas Pharmaceuticals Limited also exports these cns & psychiatric products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Escitalopram Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Escitalopram, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Escitalopram — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Escitalopram shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 396 individual customs records matching Intas Pharmaceuticals Limited exporting Escitalopram, covering 186 formulations to 10 countries via 29 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 95+ countries, 628+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Escitalopram Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Escitalopram exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Escitalopram Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Escitalopram. For current shipment-level data, contact TransData Nexus.